EML4 and non-small cell lung carcinoma: These findings indicated that SMYD2 might methylate multiple non‐histone proteins involved in proliferation/survival of NSCLC cells, as we reported previously, and treatment with SMYD2 inhibitor would be beneficial to NSCLC patients regardless of harboring EML4‐ALK fused proteins.